Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Algernon Pharmaceuticals Inc (OP: AGNPF )

0.0603 UNCHANGED
Streaming Delayed Price Updated: 1:08 PM EDT, Oct 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 100
Open 0.0603
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0603
Today's Range 0.0603 - 0.0603
52wk Range 0.0353 - 0.1230
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
DMT For Stroke Treatment: Algernon Sets Phase 2 Clinical Trial Design
Via Benzinga

Performance

YTD
-5.93%
-5.93%
1 Month
+3.97%
+3.97%
3 Month
-28.89%
-28.89%
6 Month
-32.02%
-32.02%
1 Year
+11.46%
+11.46%

More News

Read More
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
DMT As A Treatment For Stroke? This Company Is Closer To Launching Its Phase 2 Study
Via Benzinga
Algernon Posts Mixed Bag Results From Mid Stage Chronic Cough Study
Via Benzinga
DMT's Clinical Path For Treating TBI And Stroke: Phase 1 Dosing Finished As Phase 2 Gears Up
Via Benzinga
How To Finance A Psychedelics Business? Learn From These Four Companies
Via Benzinga
Intravenous DMT Therapy Seeks Ideal Dosage For Stroke And TBI Treatment
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Via Benzinga
Algernon Pharmaceuticals AP-188 DMT Compound Shows Promise For The Treatment Of TBI
Via Benzinga
Algernon Pharmaceuticals Goes 4:1 In Forward Share Split After Announcing New TBI Program
Via Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
Via Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
Via Benzinga
Developing Psychedelic Treatments For Traumatic Brain Injury: Algernon Launches New Program
Via Benzinga
Algernon Touts Positive Study Findings, Confirms Next Trial Phase With Escalated Dose
Via Benzinga
A Psychedelic Program For Treatment Of Stroke: New Clinical Trial Begins Dosing
Via Benzinga
Psychedelic Subsidiaries News: Blackhawk Spins Out Three Companies, Algernon Creates A New One
Via Benzinga
EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans
Via Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
Via Benzinga
Psychedelic Therapeutics For Human Stroke: Participant Screening Expects To Begin Soon
Via Benzinga
Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video
Via Newsfile
Tackling Depression With Psychedelics: New Phase 2 Clinical Study Begins At Yale University
Via Benzinga
A Foundational Study On Stroke Is Ready. Here Is Why It's Important
Via Benzinga
Canadian Psychedelics Company To Begin First Global DMT Clinical Trial For Stroke Treatment
Via Benzinga
Algernon Pharmaceuticals Closes Private Placement Round, Announces New Shareholder Distribution
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.